January 14, 2026 – At the 2026 J.P. Morgan Healthcare Conference, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into an exclusive global license agreement with U-mab Biopharma (Lianyungang) Co.,Ltd. ("U-mab"), a company focused on developing innovative therapies for oncology and inflammatory diseases. Under the agreement, Henlius has secured rights to a monoclonal antibody (mAb) targeting Interleukin-1 Receptor Accessory Protein (IL-1RAP) with best-in-class(BIC) potential. Building upon its core expertise in tumor immunotherapy, this partnership marks an expansion of Henlius’ efforts into immune-inflammatory diseases.

SHANGHAI, China – JANUARY 13, 2026 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Biologics License Application (BLA) for HLX04, the Company’s independently developed bevacizumab biosimilar (a recombinant anti-VEGF humanized monoclonal antibody), has been formally accepted for review by the U.S. Food and Drug Administration (FDA). The application seeks approval for the treatment of multiple solid tumours, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. This marks the fifth product submitted by Henlius for marketing approval in the United States. Previously, Henlius’ trastuzumab biosimilar HANQUYOU (trade name: HERCESSI™ in the U.S., Zercepac^® in Europe), denosumab biosimilars BILDYOS^® and BILPREVDA^®, and pertuzumab biosimilar POHERDY^® have all been successfully approved in the U.S., further demonstrating the Company’s strong capabilities in international regulatory submissions and quality management.

Happy New Year!

In 2025, Fosun steadfastly focused on its core businesses. Twelve milestones, like twelve signposts, marked every step of Fosun’s ascent throughout the year.

On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited (“TVB”), was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with the highest accolade, the “Outstanding ESG Award”, as well as awards for “Best in ESG Practices” and “Best in ESG Report”.

9 December 2025 -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use. Under the terms of the agreement, Yao Pharma will complete an ongoing YP05002 Phase 1 clinical trial in Australia and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide.

Sanya, China, On 28 November 2025, Fosun Tourism Group hosted "Fosun Holiday Horizon 2026" at Atlantis Sanya, where it systematically unveiled its three core product lines for the first time and signed 18 partnership agreements with cultural tourism investment institutions and industry partners from various regions. These developments are set to inject new momentum into the high-quality growth of China's cultural tourism sector.

A devastating fire broke out at residential buildings in Wang Fuk Court, Tai Po, New Territories, Hong Kong, resulting in casualties. Fosun Foundation, together with Fosun International, ecosystem enterprises including Fosun Pharma, Forte Hong Kong, Henlius, Fosun Wealth, Peak Re, and Fosun Asset Management, as well as singer Zhou Shen, 北京時代立方文化傳播有限公司, girl group singer i-dle, and other caring individuals and organizations, has pledged a donation of HKD10 million to support emergency relief and recovery efforts.

Shanghai, China, November 20, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab, Hetronifly^®in Europe), in combination with chemotherapy for neo-/adjuvant treatment for gastric cancer, has been officially granted the Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This marks the first gastric cancer perioperative drug to receive the CDE’s BTD. Previously, the phase 3 clinical trial of this therapy met its primary endpoints. As the world's first perioperative gastric cancer treatment regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting, it demonstrates potential to deliver dual breakthroughs in survival benefits and quality of life for patients.